Rapid Micro Biosystems, Inc. (RPID) Stock: Price, Forecast & Analyst Target
Rapid Micro Biosystems, Inc. (RPID) — MoonshotScore 22/100 (Weak band), calculated Nov 18, 2026. Price $0.7353 (-0.31%), as of the Nov 19, 2026 trading session; market cap $37.4M.
Educational signal · not a buy or sell recommendation · How to read this
Rapid Micro Biosystems, Inc. · RPID · NASDAQ
Rapid Micro Biosystems, Inc. provides microbial detection products, primarily the Growth Direct platform, for quality control in the pharmaceutical, medical device, and personal care industries. The platform automates and modernizes microbial quality control testing workflows.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Rapid Micro Biosystems (RPID)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and being loss-making and burning cash. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z -1.54 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 18 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 22 | Weak | |
| 22 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.7353 | |
| Change on the day | -0.31% | |
| 52-week range | $0.58 – $4.94 | |
| Market capitalisation | $37.4M | — |
| Shares traded on the day | 690.5K |
Price & events
Other perspectives
Council score for Rapid Micro Biosystems (RPID): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Rapid Micro Biosystems (RPID), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rapid Micro Biosystems, Inc. (RPID) is listed on NASDAQ. It employs 171 people and is led by Robert G. Spignesi Jr.. The market values it at $37.4M.
What do the latest results show for Rapid Micro Biosystems (RPID)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $7M | -$12M | — |
| Q3 FY2025 | $8M | -$12M | -$0.26 (diluted) |
| Q4 FY2025 | $11M | -$12M | -$0.28 (diluted) |
| Q1 FY2026 | $8M | -$14M | -$0.31 (diluted) |
What are the financial strengths and risks for Rapid Micro Biosystems (RPID)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -1.54 · Piotroski F 2. Trailing ratios: ROA -45.7% · current ratio 2.20.
Data-derived red flags
- Listing risk — at $0.7353 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -1.54 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Rapid Micro Biosystems (RPID)?
Short answer · as of
Current published price targets run low $0.75 · high $7.00 · consensus $3.58 · median $3.00 against a quoted price of $0.7353 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Rapid Micro Biosystems compare with its peers?
Short answer
Rapid Micro Biosystems's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $8.61 Nov 19, 2026 | $326M | 88 5-pillar Nov 18, 2026 | |
| $23.40 Nov 18, 2026 | $191M | 87 5-pillar Nov 18, 2026 | |
| $8.98 Nov 18, 2026 | $361M | 87 5-pillar Nov 18, 2026 | |
| $13.28 Nov 19, 2026 | $178M | 71 5-pillar Nov 18, 2026 | |
| $4.85 Nov 18, 2026 | $59.6M | 44 5-pillar Nov 18, 2026 | |
| $1.66 Nov 19, 2026 | $104M | 43 5-pillar Nov 18, 2026 | |
| $3.67 Nov 18, 2026 | $110M | 41 5-pillar Nov 18, 2026 | |
| $2.38 Nov 18, 2026 | $36.2M | 39 5-pillar Nov 18, 2026 | |
| $5.42 Nov 19, 2026 | $141M | 37 5-pillar Nov 18, 2026 | |
| $6.34 Nov 19, 2026 | $258M | 36 5-pillar Nov 18, 2026 | |
| $9.52 Nov 18, 2026 | $396M | 35 5-pillar Nov 18, 2026 | |
| $10.62 Nov 19, 2026 | $590M | 34 5-pillar Nov 18, 2026 | |
| Rapid Micro Biosystems (RPID) — this page | $0.7353 | $37.4M | 22 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $0.75 – $7.00
- Consensus target
- $3.58
- Median target
- $3.00
Consensus record · Captured .
Measured against a quoted price of $0.7353 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 24, 2026
- Transactions
- 20
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 0
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RPID in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RPID in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Rapid Micro Biosystems (RPID)?
What Investors Ask About Rapid Micro Biosystems (RPID)
These answers are editorial: 1 of these 9 answers is drawn from the RPID research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RPID?
RPID carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is RPID a good stock to buy?
Stock Expert AI does not rate RPID buy, sell or hold. Rapid Micro Biosystems, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RPID stock price today?
The last price recorded for Rapid Micro Biosystems, Inc. (RPID), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RPID price target?
The analyst consensus price target for Rapid Micro Biosystems, Inc. (RPID), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about RPID stock?
Analyst coverage of Rapid Micro Biosystems, Inc. is not detailed in the provided data. Therefore, a neutral summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided. Further research into recent analyst reports and financial news is needed to assess market sentiment and expectations for RPID stock.
What are the key factors to evaluate for RPID?
Rapid Micro Biosystems, Inc. (RPID) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. As the installed base of systems grows, the demand for consumables will increase proportionally. Not financial advice.
How frequently does RPID data refresh on this page?
RPID's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RPID's recent stock price performance?
Rapid Micro Biosystems, Inc. (RPID) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Growth Direct platform automates and accelerates microbial quality control testing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RPID overvalued or undervalued right now?
Rapid Micro Biosystems, Inc. (RPID) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 11 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com